Cerevel Therapeutics Development Pipeline Challenges the Longstanding Dominance of AbbVie Neuroscience Portfolio
The pharmaceutical landscape is witnessing a significant shift as specialized biotechnology firms begin to encroach upon territories once considered the exclusive domain
